Lineage Cell Therapeutics
LCTX
LCTX
94 hedge funds and large institutions have $48.5M invested in Lineage Cell Therapeutics in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
8% less capital invested
Capital invested by funds: $52.9M → $48.5M (-$4.41M)
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
Holders
94
Holding in Top 10
3
Calls
$96K
Puts
–
Top Buyers
| 1 | +$702K | |
| 2 | +$665K | |
| 3 | +$284K | |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$219K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$200K |
Top Sellers
| 1 | -$4.99M | |
| 2 | -$1.49M | |
| 3 | -$902K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$570K |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
-$350K |